Clinical Trial Update: Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results for lintuzumab-Ac225 in older adults with acute myeloid leukemia have been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Lintuzumab-Ac225 (lintuzumab-actinium-225)

Snippet

Sponsor: Actinium Pharmaceuticals | Conditions: AML | Phase 1, Phase 2 | Status: COMPLETED